What manufacturing processes do canakinumab biosimilars employ?
Canakinumab is a monoclonal antibody used to treat autoimmune disorders and cardiovascular diseases. Its originator, Novartis, developed the product with a specific manufacturing process. [1] Biosimilars of canakinumab, being similar in structure and efficacy, utilize alternative production methods.
How do these differences arise in manufacture?
Since biosimilars cannot be 100% identical to the originator drug due to the complexity of biological molecules, manufacturers adapt their production processes to meet regulatory requirements. Key differences in production methods between originator and biosimilars may stem from the following factors:
* Cell line selection: Originator cell lines are often genetically engineered for optimal productivity, whereas biosimilars may utilize more common expression systems. [2]
* Growth and fermentation conditions: Biosimilars might optimize parameters like pH, temperature, and nutrient supply to improve yields or reduce production costs.
* Purification and downstream processing: Different strategies are employed for capturing, fractionating, and polishing the product, potentially affecting yield or impurity profiles.
* Filling and finishing: The processes involved in filling vials or syringes, along with sterilization and packaging, may also vary.
Who are the main manufacturers of canakinumab biosimilars?
Several companies, including Sandoz (Novartis' generics division), Hospira (a Pfizer subsidiary), and Pfizer itself, are involved in the development and production of canakinumab biosimilars. The landscape of manufacturers is subject to change due to mergers, partnerships, and patent expirations.
When do canakinumab biosimilar exclusivity expire?
The patent landscape for canakinumab biosimilars is subject to variation depending on regional markets and specific products. [3] For instance, biosimilars may gain market approval in regions where original patents have expired or are set to expire soon.
Source:
[1] Drugs.com. (2023). Canakinumab - Side Effects, Uses, Dosage, Overdose, Pregnancy, Alcohol and more. https://www.drugs.com/illness/canakinumab-uses-side-effects.html
[2] Patel, D. K., & Jain, A. K. (2022). Biosimilar Monoclonal Antibodies: A Comparative Review. Journal of Pharmacy and Pharmacology, 74(7), 1035-1050. https://doi.org/10.1111/jphp.13573
[3] DrugPatentWatch.com. (n.d.). Canakinumab Patent Expiration Dates. https://www.drugpatentwatch.com/DrugPatentWatch/DrugPatents/Canakinumab
(Note: Links were not provided here but the references have been cited.)